More Problems in Indian Generics - FDA

#1

FDA Inspectors Again Find Dangerous Breakdowns at an Indian Factory Supplying Medications to U.S. Consumers

“U.S. inspectors have uncovered new and dangerous breakdowns in drugmaking at an Indian factory owned by Sun Pharma that produces generic medications for American consumers.

The latest problems come 2 1/2 years after the Food and Drug Administration gave the facility a special pass to continue sending certain drugs made there to the United States, even after the factory was officially banned from the U.S. market.“

Sun Pharma is the biggest pharmaceutical manufacturer in India and one of the biggest in the world. No company is exempt from having these problems in India or elsewhere, but it underlines yet again that if you are playing russian roulette with meds from the biggest and most established companies out there, you are taking all the more risks with smaller companies that have no presence in the US and not even nominal FDA checks.

Buyer beware, for the thousandth time.

10 Likes
#2

Does anyone know if the FDA does these inspections in all countries that make drugs or precursors that get imported to the US?

1 Like
#3

Now I’m concerned about that brilloez nexlizet…

What do people make of cipla?

===

Claude Opus 4:
Based on my research, here’s a comprehensive overview of India’s most important pharmaceutical manufacturers and their quality standards:

Top Indian Pharmaceutical Companies (2025)

1. Sun Pharmaceutical Industries

  • Market Cap: ₹3,71,000 crore ($28.7 billion)
  • Global Ranking: 4th largest specialty generic manufacturer globally
  • Quality Standards:
    • 43 manufacturing facilities with 14 dedicated to APIs
    • Faced FDA warning letter for CGMP violations including inadequate cleaning and maintenance of equipment, with repeated violations at multiple sites
    • Despite challenges, maintains strong global presence in 100+ countries

2. Dr. Reddy’s Laboratories

  • Revenue: $2.9+ billion
  • Specialties: Gastroenterology, cardiovascular, diabetology, oncology
  • Quality: Founding member of Indian Pharmaceutical Alliance
  • Plans to triple customer reach by 2030

3. Cipla Limited

  • Market Share: 5.4% of Indian pharmaceutical market
  • Leadership: #1 in respiratory segment (24.6% market share)
  • Quality Issues: FDA warning for inadequate investigations into quality defect complaints and media fill contamination incidents
  • Accreditations: USFDA, EDQM, WHO, TGA Australia, PMDA Japan

4. Divis Laboratories

  • Revenue: ₹7,625.30 crore (2024)
  • Focus: APIs and intermediates, high-potency compounds
  • Quality: Renowned for high-quality standards and innovation

5. Lupin Limited

  • Presence: Operations in 100+ countries
  • Focus: Cardiovascular, diabetology, anti-infectives
  • Quality: Strong emphasis on regulated markets (US, Japan, Australia)

Quality Standards Overview

FDA Compliance Performance

  • In 2023, Indian facilities showed better regulatory outcomes than global average, with 13% classified as OAI (Official Action Indicated) versus 15% global average
  • In 2024, OAI cases decreased to 14 (from 18 in 2023), showing improvement in compliance
  • Indian companies secure 48-50% of all USFDA abbreviated new drug approvals

WHO Standards

  • India supplies 70% of WHO vaccines and contributes 57% of APIs to WHO’s prequalified list
  • India has the highest number of USFDA-compliant pharmaceutical manufacturing facilities

Common Quality Issues

  1. Data Integrity: Multiple companies faced violations for inadequate record-keeping
  2. Manufacturing Practices: Issues with cleaning procedures, quality control
  3. Investigation Procedures: Inadequate investigation of quality complaints
  4. Management Oversight: Systemic issues requiring corporate-level interventions
3 Likes
Generally Good Indian Pharma Companies
#4

openAI o3 much better:

Below is an at‑a‑glance map of India’s biggest drug makers (by market cap / revenue in FY 2024‑25¹) and how regulators have judged their manufacturing quality since 2023.
Legend — Overall quality signal:

  • ▲ Robust = no open FDA/EMA/WHO findings & no quality‑linked recalls in the last two years.
  • △ Mixed = isolated recalls or Form 483 observations that were either minor or quickly remediated.
  • ▼ Red flag = recent FDA Warning Letter, EMA GMP‑non‑compliance statement, import alert or multiple class‑II recalls.
Rank ≈ Company (HQ) What makes it “important” Recent quality record (2023‑25) Signal
1 Sun Pharmaceutical Inds. (Mumbai) India’s largest pharma group; ₹52,578 cr FY 25 revenue 2025 FDA inspection at Halol found bacteria, metal and mold; eight fresh 483 observations and multiple U.S. recalls for febuxostat, methylphenidate & metformin ProPublicaThe Times of IndiaCoalition For A Prosperous America ▼
2 Divi’s Laboratories (Hyderabad) World‑top API supplier; low finished‑dose exposure Only warning letter was in 2017; FDA close‑out issued the same year and no citations since U.S. Food and Drug AdministrationU.S. Food and Drug Administration ▲
3 Cipla Ltd. (Mumbai) #3 by revenue; strong U.S./Africa footprint Goa solid‑dose site received FDA warning letter Nov 2023; no follow‑up enforcement yet. FY 25 revenue ₹27,548 cr U.S. Food and Drug Administrationmint △
4 Dr. Reddy’s Labs (Hyderabad) #4 by revenue; large injectable & complex‑generic play 2024 potency recall (Sapropterin) and 2025 mis‑label recall (Levetiracetam). Srikakulam formulation site got a 4‑observation 483 (resolved as VAI) U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationFierce Pharma △
5 Torrent Pharma (Ahmedabad) Leading cardio‑metabolic portfolio 2022 483 cited unsanitary conditions and un‑investigated defects at Indrad plant Fierce Pharma △
6 Mankind Pharma (Delhi) Fast‑growing domestic leader; limited U.S. exposure No FDA warning letters to date; only device‑grade 510(k) clearances and routine inspections (e.g., 2025 Behror site) FDA Access DataU.S. Food and Drug Administration ▲
7 Zydus Lifesciences (Ahmedabad) Top vaccines & chronic therapies exporter Aug 2024 FDA warning letter plus two Form 483s in 2024 citing glass/particulate risk & cross‑contamination U.S. Food and Drug AdministrationFierce Pharma ▼
8 Lupin Ltd. (Mumbai) Major inhalation & biosimilar pipeline Recalls of oral contraceptives (2023) and multiple Form 483s across Indian plants; one Nagpur site cleared with zero observations in 2024 Fierce PharmaFierce PharmaFierce Pharma △
9 Aurobindo Pharma / Eugia (Hyderabad) Top 5 U.S. generic filer Five separate Form 483s since 2024; Eugia sterile plant now “Official Action Indicated” for microbial‑control failures Fierce PharmaFierce Pharma ▼
10 Biocon Biologics (Bengaluru) India’s biosimilar champion; EU‑ & US‑approved insulins No recent GMP citations; June 2025 FDA pre‑notice relates only to trial‑data posting, not manufacturing U.S. Food and Drug Administration ▲
11 Intas Pharmaceuticals (Ahmedabad) Large private generics group (Accord EU) 2023 FDA warning letter after inspectors found “truckloads of shredded QC records” and data integrity breaches; EU placed site under GMP non‑compliance Fierce PharmaRAPS ▼
12 Granules India (Hyderabad) Mid‑tier but key U.S. acetaminophen supplier Sept 2024 FDA 483 over destroyed batch records; Feb 2025 FDA warning letter highlighting CGMP failures Fierce PharmaU.S. Food and Drug Administration ▼

How to read this table

  • Market Importance: Ranked roughly by FY 24‑25 revenue/market‑cap (Sun > Divi’s > Cipla > Dr Reddy’s … Granules).¹
  • Quality Signals: Drawn from public FDA/EMA documents, WHO alerts, CDSCO test failures and major recalls in 2023‑25.
  • Granularity: A single company can operate 10‑40 plants. One red‑flag site does not condemn every product, but persistent multi‑site findings generally correlate with higher recall rates and import alerts.
  • Caveats: “Good” (▲) does not guarantee perfect quality; it only means no regulatory body has publicized a serious lapse recently. Always check the specific ANDA holder and lot when you buy a generic drug.

Bottom line

Indian pharma ranges from world‑class API and biosimilar outfits (Divi’s, Biocon) to serial violators still struggling with data integrity (Intas) or contamination controls (Sun’s Halol, Aurobindo’s Eugia). When product choice matters—e.g., long‑term chronic therapy—checking who made your pill and how often that firm has been on the FDA’s radar is your best defence against hidden impurities.

¹ Forbes India market‑cap list (June 19 2025) & FY 25 pharma‑results press releases were used to establish relative size.

4 Likes
Generally Good Indian Pharma Companies
#5

Here you go: South Korea.

FDA hands down citations to 3 drugmakers after inspections found contamination, testing concerns

https://www.fiercepharma.com/manufacturing/fda-hands-down-manufacturing-citations-3-drugmakers-after-inspections-found

“Meanwhile, a Daewoo Pharm site in Busan, Korea, received a warning letter on July 2 after an FDA inspection earlier this year. The company had replied to a previous Form 483 in February, but its responses were largely viewed as inadequate, leaving the plant’s products currently considered “adulterated” by the FDA due to “significant” violations of manufacturing regulations.

The agency listed five main concerns in the contamination, quality control and cleanliness realms with evidence ranging from improper sterilization of equipment to inadequate environmental monitoring and visual inspection. Some of the more damning examples cited by the FDA was mold in “multiple areas” of the facility that Daewoo failed to properly investigate, plus late testing on certain samples despite a “substantial number of complaints for burning or redness,” which suggested potential contamination.

Daewoo’s site has also failed to maintain a robust sampling and testing plan for a component. Contamination of that component at other manufacturers has in the past resulted in “various lethal poisoning incidents in humans worldwide,” the FDA notes.

The Korean drugmaker specializes in ophthalmology and pledges to “take care of the eye health of people across the world.” The company’s Busan plant makes tablets, capsules and eye drops and sells its products in Targets and Walgreens across the U.S.”

2 Likes
#6

I think this type of information could be very deceiving… I don’t believe that the FDA isn’t going to care much about Domestic India Pharma, so the fact that they’ve gotten no FDA warning letters means nothing… I think this is an example of how LLMs are still in their infancy and not to be entirely trusted or believed.

4 Likes
#7

Here you go: Taiwan. This is a voluntary recall of pitavastatin tablets.

More than 57,000 Bottles of a Cholesterol Medication Have Been Recalled in One State

" Orient Pharma Co., Ltd. Yunlin Plant in Taiwan is listed as the recalling firm. Evidently, the company voluntarily initiated the recall on June 11. However, the FDA didn’t assign the recall a Class III label until Wednesday, July 16.

Class III recalls involve situations in which “use of or exposure to a violative product is not likely to cause adverse health consequences,” per the FDA website."

1 Like
#8

“Evidently, the company voluntarily initiated the recall on June 11. However, the FDA didn’t assign the recall a Class III label until Wednesday, July 16.”

Our government funding cuts at work! Well-played

2 Likes
#9

At this point, I would avoid Glenmark completely. The problems are so severe, so widespread, and so persistent, I think the risk is so high that one should 100% avoid this manufacturer.

The FDA Is Cracking Down on an Indian Drugmaker Investigated by ProPublica Last Year

"In December, ProPublica reported that a Glenmark Pharmaceuticals factory in central India was responsible for an outsized share of recalls for pills that didn’t dissolve properly and could harm American patients. Among the string of recalls, federal regulators had determined that more than 50 million potassium chloride extended-release capsules sold in the U.S. could be deadly. Yet, federal drug inspectors at that point hadn’t set foot in the Madhya Pradesh factory for more than four years, ProPublica found.

Seven weeks after that story was published, FDA inspectors showed up at the plant and found serious problems. Glenmark subsequently recalled an additional two dozen medicines made there and sold to U.S. patients.

Now the FDA has sent Glenmark a warning letter, a disciplinary tool the regulator uses to lay out significant violations of federal requirements and demand changes. If Glenmark fails to fix any of the problems outlined, the FDA warned, it may bar drugs made at the factory from entering the U.S.

What’s more, the FDA pointed out that the company had made similar serious mistakes at three other manufacturing sites and acknowledged that those factories had been the subject of previous warning letters from the agency since 2019. The problems at one were so severe that federal regulators blocked drugs made there from being imported to Americans. ProPublica’s December investigation highlighted this pattern, noting that three of the five factories where Glenmark made drugs for the U.S. market in recent years had been in trouble with federal regulators. Despite that track record, the FDA — backlogged from the pandemic — waited five years before sending its inspectors back to the Madhya Pradesh plant.

In his July 11 warning letter, the director of the FDA’s Office of Manufacturing Quality wrote, “These repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs is inadequate.” (The agency made the letter publiclast week.)"

4 Likes
#10

I was shocked to see some extremely common medications given a pass by the FDA (example: atorvastatin) despite documented and uncorrected manufacturing problems. It’s a pretty big list given here (you have to click through the 4 pages of the table to get the full list):

The FDA Let Substandard Factories Ship These Medications to the U.S.

"For more than a dozen years, the Food and Drug Administration quietly allowed substandard foreign factories to continue shipping medications to the United States even after the agency officially banned them from doing so because of dangerous manufacturing failures.

ProPublica exposed the little-known practice in June. The FDA said the decisions to exempt certain medications from import bans were made to fend off drug shortages and that guardrails were in place to ensure the products were safe, such as requiring the banned factories to do extra testing on the drugs before they were sent to Americans.

But the agency itself didn’t regularly test the drugs or proactively monitor reports filed by doctors and others that described drugs with a foul odor, abnormal taste or residue, or consumers who had experienced sudden or unexplained health problems. The FDA cautions the outcomes described in the complaints may have no connection to the drugs or could be unexpected side effects. But drug safety experts say that without further study, it’s impossible to know whether people were harmed or how many.

“The FDA kept the exemptions largely hidden from the public and has never released a comprehensive list of the drugs allowed into the United States from banned factories. ProPublica is publishing that list today.”

3 Likes
#11

Holy… Just bought Glenmark Telmisartan, fortunately not in the recall list…

81kfoMR9QPL.SL1500
81kfoMR9QPL.SL15001500×1500 168 KB

2 Likes
#12

“Unacceptable”: Prominent U.S. Senators Demand FDA Provide Names of Troubled Foreign Drugmakers Skirting Import Bans

2 Likes
#13

The FDA has their hands full with wanting to stop so-called counterfeit drugs by having the right to inspect all incoming packages, and this long standing problem. Their funding has been cut, it’s hard to see how they’ll approve either objective.

1 Like
#14

Here’s What Happened When ProPublica Reporters Tried to Find Out Where a Popular Prescription Drug Was Made

3 Likes
#15

Regular reminders of why you want to avoid the lower tier Indian pharma companies:

4 Likes
#16

FDA Announces Nationwide Recall of Cholesterol Medication—More Than 140,000 Bottles Affected

4 Likes
#17

If anyone is interested in which lab:

The recall currently only affects bottles of 10mg, 20mg, 40mg and 80mg atorvastatin calcium tablets manufactured by Alkem Laboratories, Ltd., of India, and distributed by Ascend. The recalled bottles contained different quantities of the tablets, ranging from 90-count to 1000-count bottles. Just under 142,000 bottles of the 10mg medication were involved in the recall; the quantity of recalled bottles containing 20mg, 40mg and 80mg tablets was listed in the FDA’s enforcement report.

3 Likes
#18
1 Like
#19

Very interesting topic and helpful articles linked, thanks!

I was working with Claude to sort rankings for Indian manufacturers for items Americans other others seek to buy from India (like Telmisartan or Amlodipine among others). I added the articles and studies referenced here as well as the rankings others created and I’m felling relatively confident in my current rankings. I would appreciate any feedback on the accuracy of these rankings:

Indian Pharmaceutical Manufacturer Tier Rankings
For US patients sourcing oral solid dose medications from India

How rankings were created: Based on FDA warning letters, import alerts, Form 483 inspection observations, recall records, and investigative reporting (primarily ProPublica) from 2020–2026. Rankings weight severity of violations over frequency, since larger companies face more inspections. Data integrity violations (falsified/destroyed records) are treated as disqualifying regardless of company size.
Key limitations: FDA inspections of Indian facilities were pre-announced until May 2025, meaning compliance records likely understate real-world risk. Individual pill bottles rarely identify the specific manufacturing facility, so even a good manufacturer tier doesn’t guarantee a specific product came from a clean facility.

TIER 1 — Acceptable
No active warning letters, no active import alerts, clean or improving inspection record 2022–2026
• Alembic — Cleanest record in the dataset; no warning letters; supplied nitrosamine-free sartans during the contamination crisis
• Torrent — Historical sartan recalls resolved; Pithampur facility upgraded to clean VAI status November 2024; avoid for ARBs from legacy lots
• Ajanta — No warning letters or import alerts; focused specialty portfolio
• JB Chemicals — No enforcement actions; KKR ownership adds governance layer
• Micro Labs — No enforcement actions; primarily domestic-focused
• Dr. Reddy’s — Frequent minor recalls but no active warning letter; size-normalized compliance record is acceptable
• Mankind — No FDA warning letters; dominant domestic market player with limited but clean US footprint

TIER 2 — Use With Caution
Past warning letters resolved or in active remediation; mixed inspection record; no acute disqualifying action
• Lupin — Upgraded from Tier 3; Nagpur and Pithampur Unit-3 oral solid sites running clean 2024–2026; legacy Goa and Indore sites still generating 483s
• Zydus — Upgraded from Tier 3; August 2024 warning letter formally closed December 2025; multiple VAI resolutions; long history of multi-site issues warrants ongoing caution
• Cipla — Two simultaneous unresolved warning letters (Pithampur, Goa); oral solid dose facilities less affected than inhalers but management oversight findings are company-wide
• Alkem — No warning letter yet, but atorvastatin (141,000 bottles) and metoprolol dissolution failures at Baddi suggest an emerging pattern; watch closely
• Macleods — No warning letters; losartan nitrosamine recalls linked to Hetero-supplied API rather than own manufacturing failure; thyroid products flagged by CDSCO
• Natco — April 2024 warning letter formally closed September 2025; rapid resolution is positive but recency warrants caution
• Ipca — Historical import alerts now lifted; decade of prior data falsification means trust must be rebuilt gradually
• Piramal — CDMO-focused; clean record with minor sterile manufacturing 483s
• Laurus — Primarily API/CDMO; minor 483 observations; limited finished dose relevance
• Jubilant — Historical import alert resolved; currently clean
• FDC — No enforcement actions; minimal US footprint limits available data
• Unichem — One isolated Class I labeling recall (230 bottles); otherwise clean
• Orchid — Emerged from insolvency 2020; quality systems rebuilding; no fresh enforcement actions

TIER 3 — Avoid
Active import alerts, recent unresolved warning letters, documented data integrity violations, or ongoing contamination failures
• Glenmark — July 2025 multi-site warning letter; potassium chloride recall linked to at least 3 US deaths; repeated dissolution failures; FDA cited “inadequate management oversight”
• Sun Pharma — Halol facility under import alert since 2022; OAI re-confirmed September 2025 after fresh violations found; pattern unchanged for over a decade despite resources to fix it
• Aurobindo — Eugia sterile subsidiary received warning letter August 2024 and fresh OAI November 2025; deteriorating trajectory; 21+ recalls in recent years
• Intas — Two facilities under import alert; analyst observed pouring acid on manufacturing records during FDA inspection; data manipulation documented back to 2021
• Granules — Two warning letters in 2025; CGMP records found torn in waste bags; bird droppings near manufacturing; data integrity concerns
• Hetero — Central node in sartan nitrosamine contamination chain; facility hygiene violations (birds, lizards, cats found in warehouse); API quality failures with downstream impact on multiple companies
• Emcure — Plant banned since 2015 with no meaningful resolution over a decade; test records systematically falsified
• Strides — CGMP records found in scrap drums and awaiting shredding immediately before inspection; pre-inspection document destruction is one of the gravest possible findings
• Wockhardt — Has formally exited US generics market; multiple banned facilities; record-hiding and inspector obstruction documented

EXCLUDED — Wrong Category
Not finished oral solid dose manufacturers relevant to US retail patients
• Divi’s — API supplier only; never sells finished tablets to consumers
• Biocon — Biosimilars and biologics only
• Bharat Biotech — Vaccines only
• SPARC — Drug discovery entity; no manufacturing
• Elder — Defunct/liquidated
• Matrix/Mylan — Now Viatris (US multinational)
• Abbott India — Marketing entity only; minimal manufacturing
• Gland Pharma — Injectables only​​​​​​​​​​​​​​​​

4 Likes